SPECT/CT图像融合在分化型甲状腺癌^(131)I治疗后的临床应用价值  

Clinical application value of fusion images of SPECT/CT in patients with differentiated thyroid carcinoma after ^(131)I therapy

作　　者：林天生[1] 陈为民[1] 王申[1] 

机构地区：[1]福建医科大学附属协和医院核医学科,福建福州350001

出　　处：《中国医学影像技术》2008年第S1期202-204,共3页Chinese Journal of Medical Imaging Technology

摘　　要：目的探讨SPECT/CT图像融合在分化型甲状腺癌术后患者131I治疗后判断残余组织和转移灶的存在部位,并在确定治疗方案中的应用价值。方法对分化型甲状腺癌(DTC)术后患者30例(60例次)于131I治疗后5~7天行SPECT/CT全身和局部断层显像。131I治疗剂量为100~200mCi。结果DTC术后患者131I治疗行SPECT/CT融合图像显示:单纯残留甲状腺组织摄取131I37次,残余甲状腺和颈部淋巴结16次,纵膈和颈部淋巴结2次,双肺弥漫性及散在病灶1次,右锁骨上淋巴结1次,残余甲状腺和双肺转移2次,残余甲状腺组织和骨骼转移1次。结论SPECT/CT图像融合在131I治疗DTC后提高病灶的定位诊断、制定和调整治疗方案方面具有重要的应用价值。Objective To investigate the clinical application value of the fusion of SPECT/CT images in patients with differentiated thyroid carcinoma(DTC)after operation and 131I therapy.Methods Thirty patients of(60 times)DTC after thyroidectomy were studied using SPECT/CT images after operation and after 131I therapy 5-7 days.The therapy dosagedosagedosagedosage of 131I were 100-200 mCi.Results The result of 131I SPECT/CT fusion images showed 37 times.Radioiodine were concentrated in the remains of thyroid gland.Six...

关 键 词：SPECT/CT图像融合 甲状腺肿瘤 ^(131)I治疗 

分 类 号：R736.1[医药卫生—肿瘤]